Download Diplomate in National Board (DNB) 2019 Dec 2019 Dec PHARMACOLOGY PAPER IV Previous Question Papers
DECEMBER 2019
PHARMACOLOGY
PAPER-IV
Time: 3 hours PHARM/D/19/34/lV
Max. Marksz100
Important Instructions:
. Attempt all questions in order.
Each question carries 10 marks.
Read the question carefully and answer to the point neat/y and leg/b/y.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer all the parts of a single question together.
Start the answer to a question on a fresh page or leave adequate space between two answers.
. Draw tab/e/diagrams/?owcha/ts Wherever appropriate.
Write short notes on:
1. Give an outline about calculation of compensation if the trial participant 7+3
suffers serious adverse event in a clinical trial. Add a note on the
recommended time line of paying compensation by the sponsor after a
trial related serious adverse event.
2. Write briefly how you would help the sponsor to establish a BA-BE study 7+3
Centre for regulatory BA-BE studies following newer rules in India.
3. Describe with examples the mechanisms of action of siderophore 7+3
antibiotics. How could these agents be used to overcome bacterial
resistance?
4. Write in brief about recent advances in the treatment of rheumatoid 8+2
arthritis. How can you prevent some of the adverse effects of biologics?
5. Discuss briefly about the newer anticoagulants. What are their 6+4
advantages and disadvantages compared to conventional
anticoagulants?
6. Write a brief note on ethical considerations on research involving bio 6+4
banking. Give your comments on broad vis-a vis blanket consent for using
human biomaterials.
7. Enumerate the principles of research among vulnerable population 6+4
according to recent changes in ethical guidelines in India. What are the
protective mechanisms to safeguard their interest?
8. Elaborate with examples the recent advances, future prospects and 6+2+2
challenges of antisense oligonucleotide therapy.
9. Enumerate the essential and additional elements of informed consent 7+3
documents according to recent Indian Guidelines. in which conditions
Ethics Committee may grant waiver of consent?
10. Give an outline of expedited drug approval pathways. Make a brief note 5+5
on application of artificial intelligence in pharmacovigilance.
******~k*****
POSSESS?ION/USE OF CELL PHONES OR AN Y SUC H ELECTRONIC GADGETS [S N 07 ' PERM] 7 TE!) INSIDE HIE
EX/I MINA TION 1 1/1 LL.
This post was last modified on 17 April 2020